Phreesia Inc (PHR)

$PHR high net institutional buying including Blackrock and Vanguard. Herding outflows getting ahead of their skis on no news.

$PHR why is this going down so much today?

$PHR got back in this in the 23s with the dip after solid earnings. great low volatility sleeper

$BA $NUE $PHR $SMTC $UBER Upgrades Boost Top Stocks Today. Boeing and Nucor lead upgrades with big price target boosts https://stocksrunner.com/news/2025-06-02-power-moves-in-stock-upgrades-and-downgrades-today

$PHR Truist Lifts Price Target on Phreesia to $35 From $34, Keeps Buy Rating

$PHR - Volatility alert: Phreesia options pin risk is increasing https://www.macroaxis.com/stock-options/PHR/Phreesia?utm_source=dlvr.it&utm_medium=stocktwits

$PHR - Phreesia Inc. Common Stock - 10Q - Updated Risk Factors PHR’s 2025 10-Q risk factors reveal heightened AI-driven competition, complex growth and operational challenges, expanded cybersecurity and privacy risks, intensified client retention pressures, new India subsidiary risks, evolving regulatory burdens, payment platform uncertainties, and increased legal, financial, and geopolitical exposures—all amid ongoing market volatility and integration hurdles. #AICompetition #GeopoliticalExposure #ClientRetention #RegulatoryChallenges #CybersecurityRisks 🟢 Added 🟠 Removed https://d-risk.ai/PHR/10-Q/2025-05-28

$PHR Q1 '25 Earnings Results & Recap Phreesia Inc. reported Q1 revenue of $115.9M, beating estimates of $114.92M, and is maintaining its fiscal year 2026 revenue outlook of $472M to $482M while updating its adjusted EBITDA outlook to $85M-$90M.

$PHR numbers and outlook nice and consistent beats

$PHR (+2.2% pre) Phreesia (NYSE:PHR) Surprises With Q1 Sales https://ooc.bz/l/66036

$PHR Phreesia backs FY26 revenue view $472M-$482M, consensus $475.57M Raises FY26 adjusted EBITDA view to $85M-$90M from $78M-$88M. The company said, "We are maintaining our revenue outlook for fiscal 2026. We expect revenue to be in the range of $472 million to $482 million. The revenue range provided for fiscal 2026 assumes no additional revenue from potential future acquisitions completed between now and January 31, 2026. We are updating our Adjusted EBITDA outlook for fiscal 2026 to a range of $85 million to $90 million from a previous range of $78 million to $88 million. The Adjusted EBITDA range provided for fiscal 2026 assumes continued improvements in operating leverage across the Company through a focus on efficiency. We are maintaining our expectation for AHSCs to reach approximately 4,500 in fiscal 2026. Additionally, we expect total revenue per AHSC in fiscal 2026 to increase from fiscal 2025. We believe our $90.9 million in cash and cash equivalents as of April 30, 2025, along with cash generated in our normal operations, gives us sufficient flexibility to reach our fiscal 2026 outlook. Additionally, our available borrowing capacity under our credit facility with Capital One provides us with an additional source of capital to pursue future growth opportunities not incorporated into our fiscal 2026 outlook. As of April 30, 2025 we had no borrowings outstanding under our credit facility."

$PHR Phreesia reports Q1 EPS (7c), consensus 16c Reports Q1 revenue $115.94M, consensus $114.98M. "Our fiscal year 2026 is off to a strong start. I am grateful to our team for their continued commitment to our mission, vision and values. I believe our performance is a reflection of our team truly living our values," said CEO and co-founder Chaim Indig.

$PHR Total revenue was $109.7 million in the quarter, up 15% year-over-year. Average number of healthcare services clients ("AHSCs") was 4,341 in the quarter, up 10% year-over-year. Total revenue per AHSC was $25,266 in the quarter, up 5% year-over-year. Net loss was $6.4 million in the quarter, as compared to $30.6 million in the same period in the prior year. Adjusted EBITDA1 was $16.4 million in the quarter, as compared to negative $3.5 million in the same period in the prior year. Net cash provided by operating activities was $16.3 million in the quarter, as compared to net cash used in operating activities of $3.1 million in the same period in the prior year. Free cash flow2 was $9.2 million in the quarter, as compared to negative $10.9 million in the same period in the prior year.

$PHR bullish engulfing out of da tightness INTA 🐒🍌🧠⏰♾️

$PHR 3wt bahhhtom if da base. Is it a CERTifed low for roger to come rocking out of 🐑 amania?

Keybanc has updated their rating for Phreesia ( $PHR ) to Overweight with a price target of 28.

DA Davidson has adjusted their stance on Phreesia ( $PHR ), setting the rating to Buy with a target price of 36 → 34.

$PHR Digging PHR's healthcare tech play. Network solutions segment looking strong. Might add to position if Q2 continues this momentum. Patient engagement tech is the future. Great writeup: https://beyondspx.com/article/phreesia-inc-phr-powering-healthcare-innovation-through-a-robust-patient-centric-platform

$PHR https://wallstreetwaves.com/capture-9-9-annualized-returns-invest-in-phreesia-at-20-with-options-strategy/

Phreesia Maintains Its Momentum https://seekingalpha.com/article/4767951?gt=0cec8275290a0a58 $PHR * Phreesia remains resilient, maintaining guidance and showing strong financial performance, with Q4 revenue growth of 15% year-over-year and improved cash flow. * Despite a slight deceleration in customer growth, Phreesia's revenue per healthcare services client increased, driven by network solutions, and the company expects 13.6% revenue growth in fiscal 2026. * Future growth drivers include patient education initiatives and Post-Script Engagement, while competition is seen as beneficial, enhancing market awareness and adoption of healthcare solutions. * I continue to rate PHR stock a buy, expecting it to break out again above its previous trading range.

$PHR - Phreesia Inc. Common Stock - 10K - Updated Risk Factors PHR's 2025 10-K Risk Factors highlight intensified competition, growth management challenges, cybersecurity threats, revenue fluctuations, and regulatory impacts, with new risks from government contracts, open source software, and international laws. #Risk https://d-risk.ai/PHR/10-K/2025-03-13

Canaccord Genuity has adjusted their stance on Phreesia ( $PHR ), setting the rating to Buy with a target price of 34 → 35.